Press release, 16 April 2024 at 08:45 a.m. (EEST)

Nightingale Health, a pioneer in health risk detection and preventative health, announces today that it will open a laboratory in the United States. Additionally, Nightingale Health and the Englander Institute for Precision Medicine at Weill Cornell Medicine have signed a Letter of Intent in which the parties agree to collaborate on the adoption of Nightingale Health’s proprietary technology in healthcare and medical research in the United States.

The Englander Institute for Precision Medicine is a translational research hub at Weill Cornell Medicine committed to translating research findings into clinical practice, including at its branch campus in Doha, Qatar. The institute has already significantly impacted the field of precision medicine by developing new treatments for a variety of diseases, including cancer, rare diseases, and cardiovascular disease.

As part of the collaboration between the Englander Institute for Precision Medicine and Nightingale Health, in addition to medical research, the parties aim to integrate Nightingale Health’s proprietary blood analysis technology and disease risk assessment capabilities to Weill Cornell Medicine’s clinical and research services. The healthcare applications can be based on Nightingale Health’s existing capabilities such as multi-disease risk prediction models and individual diagnostic biomarkers that can replace clinical chemistry measures.

“We are pleased to strengthen Nightingale Health’s international presence by establishing a laboratory in the United States. This initiative complements our global network of laboratories located in Finland, Singapore, the United Kingdom and Japan, and allows us to serve the most ambitious precision medicine and healthcare projects in the world. The collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine will explore and implement ways for comprehensive risk assessment from our unique blood testing technology for patient treatment, health checks and screening programs for multiple common chronic diseases,” said Teemu Suna, Nightingale Health’s CEO and Founder.

"Our precision metabolomics pilot project marks the beginning of a new era in healthcare. The vision is to use metabolic profiling to tailor treatments uniquely for each patient, advancing precision medicine to benefit patients globally,” said Olivier Elemento, Director of Englander Institute of Precision Medicine.

The new partnerships combined with a new laboratory will make Nightingale Health well equipped to make its proprietary blood analysis technology available locally in the largest healthcare market in the world and expand its partnerships within the medical research community. The location and opening schedule of the new laboratory will be announced at a later date.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Englander Institute of Precision Medicine at Weill Cornell Medicine

The Englander Institute for Precision Medicine (EIPM) is a translational research hub at Weill Cornell Medicine that is dedicated to using precision medicine to improve patient care. Precision medicine is a personalized approach to healthcare that considers a patient's genetic makeup, lifestyle, and environment to tailor treatments to their specific needs. Founded in 2015, the EIPM advances the delivery of personalized medicine, fosters collaboration across medical and scientific disciplines, and serves as the center of innovative precision medicine care, research, and education at Weill Cornell Medicine. As a prominent research hub, EIPM is committed to translating research findings into clinical practice - Institute members implement applied genomic sequencing, artificial intelligence, informatics, and other cutting-edge technologies to personalize disease research, treatment, and prevention. Discoveries stemming from these efforts are central to identifying novel biomarkers and developing powerful targeted therapies.

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com